|
|
Post by jjacobs122 on May 19, 2020 10:59:05 GMT -5
I know that this drug is a powder that Has
to be mixed with Salinefor IV injection. Does anyone know if the size of the powder particles is compatible with our inhaler?
|
|
|
|
Post by harryx1 on May 19, 2020 12:25:04 GMT -5
|
|
|
|
Post by jjacobs122 on May 20, 2020 11:52:22 GMT -5
Interesting. I did not know that. Thank you!
|
|
|
|
Post by celo on May 25, 2020 9:33:31 GMT -5
finance.yahoo.com/news/gilead-remdesivir-most-beneficial-covid-115733828.html“A potential inhaled (nebulized) version of remdesivir (data 2H20) could increase remdesivir availability by a factor of 3x to 4x (vs. current),” Singh wrote in a note to investors. I know Mannkind doesn't use nebulizers, but could you imagine if they made a powder that could transport an antiviral directly to the alveoli affected by the virus. Maybe...
|
|
|
|
Post by barnstormer on May 25, 2020 10:27:20 GMT -5
Mannkind CEOs have made a number of presentations over the years touting and explaining the advantages of TS to safely infiltrate the enormous tissue base of the lungs to deliver insulin as well as other compounds. CV-19 is the latest, most publicized and tragic medical malady the world has seen. 100,000 lost souls so far in the US. Brazil recorded 15,000 new cases (not deaths thank god) in the last 24 hours. To date Mannkind has only garnered one CV-19 partner (Immix) who comes to the table with no credentials and no money to develop a product to aid in the effort to save lives. It was glossed over in the ASM and investors have no idea of what that relationship looks like and what they are really trying to accomplish. It is very troubling that this management team can't find any bonafide drug makers with cash other than UTHR to exploit the technology Al Mann spent a billion dollars of his own money to develop. Many investors are putting their hopes behind Hooper and Grancio to move MNKD out of the quagmire and move the company forward. That to me shows they have given up hope on their CEO. Many support Mike (as I once did) for keeping the lights on. I can't look over Mike's shoulder every day to see what he is doing to advance the value of TS and other intellectual property, but the results so far suck. But on a brighter note God bless all longs in this stock and have a safe and enjoyable Memorial Day.
|
|
|
|
Post by cretin11 on May 25, 2020 10:49:05 GMT -5
Barnstormer is correct. We have heard for year after year about TS potential to partner up on so many applications. And it’s all true. Yet we have ONE deal that’s brought us significant cash. Five years ago if you’d have said we’d have just one such deal, I’d have jumped in with the other conspiracy theorists and accuse you of being “a short posting misinformation.” As we have since learned, there really aren’t any shorts on this board posting misinformation. They don’t care to and they don’t need to, the truth is what it is.
|
|
|
|
Post by silentbob on May 28, 2020 7:57:30 GMT -5
While the molecule is certainly small enough, the dose is simply too large.
I think the dose for each inhalation is only about 1mg (could have increased slightly lately), and Remdesivir requires 100mg/day.
Even if a 75% smaller dose is required due to administration by inhalation, that is still a lot of puffs...
Mike did mention on the Q1 CC that they considered and rejected a drug because of dosage issues, and the number of inhalations he mentioned lines up with this.
So while he did not mention the drug name, I believe he was talking about Remdesivir.
Besides, Gilead is already working on their own nebulizer so that means they probably already considered and rejected other options.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on May 28, 2020 17:24:36 GMT -5
While the molecule is certainly small enough, the dose is simply too large. I think the dose for each inhalation is only about 1mg (could have increased slightly lately), and Remdesivir requires 100mg/day. Even if a 75% smaller dose is required due to administration by inhalation, that is still a lot of puffs... Mike did mention on the Q1 CC that they considered and rejected a drug because of dosage issues, and the number of inhalations he mentioned lines up with this. So while he did not mention the drug name, I believe he was talking about Remdesivir. Besides, Gilead is already working on their own nebulizer so that means they probably already considered and rejected other options. Thanks for that analysis, silentbob. I have been wondering about Remdesivir's status. |
|
